On the other hand, the addition of GLP-1 receptor agonists or non-steroidal mineralocorticoid receptor antagonists, for now, are additional second-line therapeutic strategies in people with CKD and overweight/obesity, persistent hypertension or metabolically unstable who require much tighter clinical control for the achievement of cardio-renometabolic outcomes, with the aim of delaying renal replacement therapy [62,63]. This evidence concerns the gene GLP1R and obesity disorder.